Search results
Results From The WOW.Com Content Network
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...
Lisdexamfetamine, sold under the brand names Vyvanse and Elvanse among others, is a stimulant medication that is used to treat attention deficit hyperactivity disorder (ADHD) in children and adults and for moderate-to-severe binge eating disorder in adults. [16] Lisdexamfetamine is taken by mouth. Its effects generally begin within two hours ...
Modafinil, sold under the brand name Provigil among others, is a central nervous system (CNS) stimulant and eugeroic (wakefulness promoter) medication used primarily to treat narcolepsy, [3] [8] [15] a sleep disorder characterized by excessive daytime sleepiness and sudden sleep attacks. [16]
The FDA said it was also taking steps to provide alternative treatment options. In a bid to boost the availability of the medications, in August the FDA approved several generic versions of Vyvanse.
Vyvanse (lisdexamfetamine) – a pro-drug stimulant used to treat attention deficit hyperactivity disorder and binge eating disorder; Vyvanse is converted into Dexedrine in vivo; Viibryd – an antidepressant of the serotonin modulator and stimulators class; Vivactil (protriptyline) an antidepressant also used in the treatment of nerve pain
Provigil Nevirapine [citation needed] Norfloxacin [14] Oseltamivir [citation needed] Oxicams [7] Ampiroxicam, Piroxicam, Tenoxicam, Droxicam, Lornoxicam, Meloxicam, Isoxicam: Paracetamol [15] [16] Acetaminophen, Panadol, Tylenol Penicillins [5] Phenytoin [5] Rivoraxaban [17] Xarelto: Sitagliptin [citation needed] Sulfonamides [2] Tetracycline [2
(Reuters) -The U.S. Drug Enforcement Administration has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to address the ongoing ...
Neonatal withdrawal syndrome was first noticed in 1973 in newborns of mothers taking antidepressants; symptoms in the infant include irritability, rapid breathing, hypothermia, and blood sugar problems. The symptoms usually develop from birth to days after delivery and usually resolve within days or weeks of delivery. [29]